Trial Profile
Novel Therapies for Resistant FSGS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Rosiglitazone (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Adverse reactions
- 03 Mar 2016 New trial record